Vertex Cystic Fibrosis Forecast Brightens, With Gloomy Prospects For Competition
Vertex continued its growth story in cystic fibrosis during 2017. It also chose a pair of candidates for Phase III triple combination development, threatening to virtually seal off market entry to others.
You may also be interested in...
Private start-up's acebilustat failed to improve lung function in Phase II, but the anti-inflammatory showed large numerical reductions in pulmonary exacerbations, which can be fatal.
Lacklustre top-line data from the PELICAN study raise concerns over AbbVie's commitment to Galapagos's cystic fibrosis franchise, and leaves rival Vertex even more securely in possession of the field.
Positive topline data from the ALBATROSS Phase II study suggest Galapagos's GLPG2222 is well tolerated and could bring additional therapeutic benefits to cystic fibrosis patients.